A040 Reactive oligodendrocytes promote glioblastoma progression through CCL5/CCR5-
mediated glioma stem cell maintenance, Jason Moffat, Hospital for Sick Children & University of
Toronto, Toronto, ON, Canada
From the authors' earlier publication: Targeting CCR5 with genetic knockdown or the approved drug maraviroc impairs GSC stemness and prolongs survival in GBM models. Our work highlights the functional interplay between OLs and GBM cells and positions the CCL5/CCR5 axis as a druggable target in GBM.
https://www.sciencedirect.com/science/article...7325009390
Perhaps a future collaboration...